Market Access FDA approval numbers soar after COVID troubles The FDA released its overview of 2023 and the drugs it had approved during the year.
Events Partner Content 3rd Annual Complement-based Drug Development Summit 2019 November 13-15, 2019 | Boston, MA
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
